Session

Late breaking abstracts III

DUPILUMAB IMPROVES HISTOLOGICAL AND ENDOSCOPIC FEATURES OF EOSINOPHILIC OESOPHAGITIS IN CHILDREN AGED 1–11 YEARS IN THE PHASE 3 EOE KIDS TRIAL
DUPILUMAB IMPROVES HISTOLOGICAL AND ENDOSCOPIC FEATURES OF EOSINOPHILIC OESOPHAGITIS IN CHILDREN AGED 1–11 YEARS IN THE PHASE 3 EOE KIDS TRIAL

TO THE SOURCES OF INFLAMMATORY BOWEL DISEASE: PRE-HISTORIC INTRODUCTION OF IL-23 RECEPTOR RELATED GENETIC SUSCEPTIBILITY TO INFLAMMATION INTO TODAY'S EUROPEAN POPULATION
TO THE SOURCES OF INFLAMMATORY BOWEL DISEASE: PRE-HISTORIC INTRODUCTION OF IL-23 RECEPTOR RELATED GENETIC SUSCEPTIBILITY TO INFLAMMATION INTO TODAY'S EUROPEAN POPULATION

COVID-19 VACCINE-INDUCED ANTIBODY AND T CELL RESPONSES IN IMMUNOSUPPRESSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE AFTER THE THIRD VACCINE DOSE
COVID-19 VACCINE-INDUCED ANTIBODY AND T CELL RESPONSES IN IMMUNOSUPPRESSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE AFTER THE THIRD VACCINE DOSE

POLIPROTECT VS OMEPRAZOLE IN THE RELIEF OF HEARTBURN, EPIGASTRIC PAIN AND BURNING IN NERD AND EPS PATIENTS: A RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, REFERENCE PRODUCT CONTROLLED, PARALLEL GROUP, NON-INFERIORITY CLINICAL STUDY
POLIPROTECT VS OMEPRAZOLE IN THE RELIEF OF HEARTBURN, EPIGASTRIC PAIN AND BURNING IN NERD AND EPS PATIENTS: A RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, REFERENCE PRODUCT CONTROLLED, PARALLEL GROUP, NON-INFERIORITY CLINICAL STUDY

FOUR SARS-COV-2 VACCINE DOSES OR HYBRID IMMUNITY IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES ON IMMUNOSUPPRESSIVE THERAPIES. A PROSPECTIVE, OBSERVATIONAL COHORT STUDY
FOUR SARS-COV-2 VACCINE DOSES OR HYBRID IMMUNITY IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES ON IMMUNOSUPPRESSIVE THERAPIES. A PROSPECTIVE, OBSERVATIONAL COHORT STUDY

FOUR SARS-COV-2 VACCINE DOSES OR HYBRID IMMUNITY IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES ON IMMUNOSUPPRESSIVE THERAPIES. A PROSPECTIVE, OBSERVATIONAL COHORT STUDY
FOUR SARS-COV-2 VACCINE DOSES OR HYBRID IMMUNITY IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES ON IMMUNOSUPPRESSIVE THERAPIES. A PROSPECTIVE, OBSERVATIONAL COHORT STUDY

Late breaking abstracts III  et al.

COVID-19 VACCINE-INDUCED ANTIBODY AND T CELL RESPONSES IN IMMUNOSUPPRESSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE AFTER THE THIRD VACCINE DOSE
COVID-19 VACCINE-INDUCED ANTIBODY AND T CELL RESPONSES IN IMMUNOSUPPRESSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE AFTER THE THIRD VACCINE DOSE

Late breaking abstracts III  et al.

POLIPROTECT VS OMEPRAZOLE IN THE RELIEF OF HEARTBURN, EPIGASTRIC PAIN AND BURNING IN NERD AND EPS PATIENTS: A RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, REFERENCE PRODUCT CONTROLLED, PARALLEL GROUP, NON-INFERIORITY CLINICAL STUDY
POLIPROTECT VS OMEPRAZOLE IN THE RELIEF OF HEARTBURN, EPIGASTRIC PAIN AND BURNING IN NERD AND EPS PATIENTS: A RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, REFERENCE PRODUCT CONTROLLED, PARALLEL GROUP, NON-INFERIORITY CLINICAL STUDY

Late breaking abstracts III  et al.

TO THE SOURCES OF INFLAMMATORY BOWEL DISEASE: PRE-HISTORIC INTRODUCTION OF IL-23 RECEPTOR RELATED GENETIC SUSCEPTIBILITY TO INFLAMMATION INTO TODAY'S EUROPEAN POPULATION
TO THE SOURCES OF INFLAMMATORY BOWEL DISEASE: PRE-HISTORIC INTRODUCTION OF IL-23 RECEPTOR RELATED GENETIC SUSCEPTIBILITY TO INFLAMMATION INTO TODAY'S EUROPEAN POPULATION

Late breaking abstracts III  et al.

DUPILUMAB IMPROVES HISTOLOGICAL AND ENDOSCOPIC FEATURES OF EOSINOPHILIC OESOPHAGITIS IN CHILDREN AGED 1–11 YEARS IN THE PHASE 3 EOE KIDS TRIAL
DUPILUMAB IMPROVES HISTOLOGICAL AND ENDOSCOPIC FEATURES OF EOSINOPHILIC OESOPHAGITIS IN CHILDREN AGED 1–11 YEARS IN THE PHASE 3 EOE KIDS TRIAL

Late breaking abstracts III  et al.

Item 1 - 10 / 10
1